Concord Biotech Ltd. witnessed strong buying interest on June 3, 2026, with its shares surging more than 8% after the company announced that it had secured approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.

The approved drug is an immunosuppressant used to prevent organ rejection in adult and pediatric patients who have undergone kidney, heart, or liver transplants. It is typically administered in combination with other immunosuppressive therapies and serves a critical role in post-transplant care.

The regulatory clearance marks another milestone in Concord Biotech’s strategy to expand its footprint in the US generics market. The company already has a strong presence in immunosuppressant therapies and has received multiple USFDA approvals in recent years across its formulations portfolio.

According to market estimates, the US market opportunity for Mycophenolate Mofetil is approximately $30 million annually. The approval is expected to support future revenue growth and strengthen Concord Biotech’s position in the highly regulated pharmaceutical market.

The stock's sharp rise reflected positive investor sentiment toward the development, with the approval viewed as an important addition to the company’s growing portfolio of complex generic products. Market participants also noted that the approval reinforces Concord Biotech’s capabilities in developing and commercializing specialized therapies for global markets.